title: [Intravenous and subcutaneous immunoglobulin therapy].
abstract: Patients with agammaglobulinaemia and hypogammaglobulinaemia require immunoglobulin G (IgG) replacement therapy to prevent serious infections. Since the 1950s, therapy with human immune globulin products has been the standard of treatment. Currently, the most common routes of administration of IgG replacement therapy are intravenous (IVIG) or subcutaneous (SCIG). The home therapy may improve the quality of life in patients who require lifelong IgG replacement. The -anti-IgA antibody test identifies the patients with the risk of anaphylactoid reactions in IVIG replacement. The SCIG delivery may be used in patients with anti-IgA antibodies and previous systemic reactions to IVIG.
authors: Ustav klinicke imunologie a alergologie, Lekarska fakulta, Masarykovy University a FN u sv. Anny v Brne. vojtech.thon@fnusa.cz
authors: Vojtěch
authors: V
authors: Thon
mesh_terms: D000361:Agammaglobulinemia / Q000188:drug therapy*; D000888:Antibodies, Anti-Idiotypic / Q000097:blood; D006801:Humans; D007116:Immunization, Passive; D007074:Immunoglobulin G / Q000008:administration & dosage*; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects / Q000627:therapeutic use*; D007279:Injections, Subcutaneous
chemical_list: D000888:Antibodies, Anti-Idiotypic; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; C049937:anti-IgA